A shadow over the promising inhaled interferon beta COVID-19 therapy has been cleared with the discovery that although it appears to increase levels of ACE2 protein — coronavirus’ key entry point into nose and lung cells — it predominantly increases levels of a short version of that protein, which the virus cannot bind to.